During the recent session, Fate Therapeutics Inc (NASDAQ:FATE)’s traded shares were 0.39 million, with the beta value of the company hitting 1.84. At the last
In the last trading session, 4.5 million shares of the Fate Therapeutics Inc (NASDAQ:FATE) were traded, and its beta was 1.87. Most recently the company’s
In the last trading session, 24.73 million shares of the Fate Therapeutics Inc (NASDAQ:FATE) were traded, and its beta was 1.86. Most recently the company’s
Fate Therapeutics Inc (NASDAQ:FATE)’s traded shares stood at 1.75 million during the last session, with the company’s beta value hitting 1.84. At the close of
Fate Therapeutics Inc (NASDAQ:FATE)’s traded shares stood at 1.8 million during the last session, with the company’s beta value hitting 1.84. At the close of
Fate Therapeutics Inc (NASDAQ:FATE)’s traded shares stood at 1.76 million during the last session, with the company’s beta value hitting 1.86. At the close of
In the last trading session, 1.12 million Fate Therapeutics Inc (NASDAQ:FATE) shares changed hands as the company’s beta touched 1.88. With the company’s per share
In last trading session, Fate Therapeutics Inc (NASDAQ:FATE) saw 1.22 million shares changing hands with its beta currently measuring 1.90. Company’s recent per share price
Fate Therapeutics Inc (NASDAQ:FATE) has a beta value of 1.87 and has seen 1.29 million shares traded in the last trading session. The company, currently
Fate Therapeutics Inc (NASDAQ:FATE) has a beta value of 1.88 and has seen 2.25 million shares traded in the last trading session. The company, currently
Marketing Sentinel delivers exclusive content, news, articles, and comprehensive coverage of events in the USA and worldwide with a commitment to reliability, objectivity, and timeliness.
© 2024, Powered by Smart TechOne
